Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?

Why sovereign AI should reinforce rather than undermine the AI capex cycle?

Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?

Australia’s Ampol logs record half-year profit with more than four-fold rise

The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.

Earnings call transcript: Chorus posts stronger FY 2026 profit, lifts dividend outlook

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

UK productivity showing sustained improvement, economists say

Analysis-China’s property crisis grinds on after Evergrande sentencing

Fast fashion giant Shein valued at up to $27 billion in Hong Kong IPO